New York, USA (CU)_ An antiviral tablet was shown to significantly lower the risk of hospitalization and mortality in individuals diagnosed with COVID-19 by 50% during the clinical studies. The medication is named Molnupiravir and is manufactured by Merck and Ridgeback Biotherapeutics in the United States. According to the media, it has been shown to be consistently effective against all COVID-19 variants, including the extremely infectious delta form. Based on the trial’s findings, the business aims to file an application to the US Food and Drug Administration (FDA) for emergency use permission as soon as possible.
According to Merck, if approved, Molnupiravir would be the first…
